1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow Pleural Effusion, Malignant: new trials by email Literature Review of Pleural Effusion, Malignant trials Research Report on Pleural Effusion, Malignant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment ILX-295501 - Fallopian Tube Cancer, Metastatic Cancer | Phase 2 | Withdrawn | Genzyme, a Sanofi Company | 1999-05-01 | 2018-09-18 |
Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1)
Adnexal Diseases (1) · Carcinoma (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1)
N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea (1)
United States (1)
Gayle Cook, RN (1)